Dr. Zina Meriden, MD

Dr. Meriden practices at Boca Raton Psychiatry in Parkland, Florida.

Dr. Meriden's NPI, 1790943496, was assigned on May 29, 2008. Dr. Meriden graduated from Perelman School of Medicine - Philadelphia in 2008. Dr. Meriden holds Florida license ME126366.

Dr. Meriden's primary practice is Boca Raton Psychiatry, at 7887 Blue Sage Way, Parkland, FL 33076 in Broward County. The practice phone is (561) 342-8822.

Dr. Meriden's primary practice is Boca Raton Psychiatry in Parkland, Florida. The medical group on file is Boca Raton Psychiatry. Dmand AI also links Dr. Meriden to 1 more group practice or clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Meriden practices. Vendor and product names are available with a free account.

Psychiatry is Dr. Meriden's primary specialty in the NPI Registry, under taxonomy code 2084P0800X. Dr. Meriden is board certified in psychiatry by the American Board of Psychiatry and Neurology. Dmand AI has Dr. Meriden's licenses on file in 14 states: Florida, Colorado, District of Columbia, New York, Tennessee, California, Illinois, Massachusetts, North Carolina, Pennsylvania, Virginia, Indiana, Maryland and Texas.

Dmand AI lists anxiety, bipolar disorder, depression, insomnia, non-alzheimer's dementia (chronic) and psychoses among the conditions Dr. Meriden treats.

CMS data shows 207 Medicare services from Dr. Meriden across 4 procedure codes in 2024, for 76 Medicare patients. Medicare paid $18,469 for them.

CMS counts 76 Medicare patients who saw Dr. Meriden in 2024. The largest group is under 65, with 32 patients. 75% of them have anxiety, and 75% have high blood pressure. 55% are also on Medicaid. Their average risk score is 2.02, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Meriden's median patient age at 40, with 57% women.

In 2024, Dr. Meriden wrote 904 Medicare Part D claims for 134 patients. 98% of them were for generic drugs. CMS names the drug for 712 of them, across 23 drugs with 11 or more claims each, at $10,892 in total drug cost. In 2023, CMS named 380 claims across 15 drugs.

Dr. Meriden accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Meriden as offering telehealth.

Dmand AI links 11 papers to Dr. Meriden, published from 2009 to 2023. The most frequent topics are Pancreatic Neoplasms. Dr. Meriden's most frequent co-authors are Hugo Bonatti, MD, Richard David Schulick, MBA, MD and Nadine S. Aguilera, MD.

Dmand AI links Dr. Meriden to 3 clinical trials. Conditions studied include Schizophrenia and Schizophrenia Spectrum and Other Psychotic Disorders. ACADIA Pharmaceuticals Inc. sponsors the most, 3. Open Payments lists research payments to Dr. Meriden that name 3 trials.

CMS Open Payments shows 19 general payments to Dr. Meriden from 9 drug and device companies from 2019 to 2025. Food and beverage make up the largest share, 100% of the total. Janssen Pharmaceuticals, Inc paid the most, $321. It also lists 4 research payments totaling $52,710 in 2017, naming 3 clinical trials.

Dmand AI lists 12 awards for Dr. Meriden, most recently Honors Scholar in 2015.

Dr. Meriden graduated from Perelman School of Medicine - Philadelphia in 2008.

Dr. Meriden is in network with 12 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 9. Check the plan with the practice before a visit.